Tags

Type your tag names separated by a space and hit enter

Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.
J Mass Spectrom. 2003 Jun; 38(6):659-76.JM

Abstract

The classical stimulants amphetamine, methamphetamine, ethylamphetamine and the amphetamine-derived designer drugs MDA, MDMA ('ecstasy'), MDEA, BDB and MBDB have been widely abused for a relatively long time. In recent years, a number of newer designer drugs have entered the illicit drug market. 4-Methylthioamphetamine (MTA), p-methoxyamphetamine (PMA) and p-methoxymethamphetamine (PMMA) are also derived from amphetamine. Other designer drugs are derived from piperazine, such as benzylpiperazine (BZP), methylenedioxybenzylpiperazine (MDBP), trifluoromethylphenylpiperazine (TFMPP), m-chlorophenylpiperazine (mCPP) and p-methoxyphenylpiperazine (MeOPP). A number of severe or even fatal intoxications involving these newer substances, especially PMA, have been reported. This paper describes a method for screening for and simultaneous quantification of the above-mentioned compounds and the metabolites p-hydroxyamphetamine and p-hydroxymethamphetamine (pholedrine) in human blood plasma. The analytes were analyzed by gas chromatography/mass spectrometry in the selected-ion monitoring mode after mixed-mode solid-phase extraction (HCX) and derivatization with heptafluorobutyric anhydride. The method was fully validated according to international guidelines. It was linear from 5 to 1000 micro g l(-1) for all analytes. Data for accuracy and precision were within required limits with the exception of those for MDBP. The limit of quantification was 5 micro g l(-1) for all analytes. The applicability of the assay was proven by analysis of authentic plasma samples and of a certified reference sample. This procedure should also be suitable for confirmation of immunoassay results positive for amphetamines and/or designer drugs of the ecstasy type.

Authors+Show Affiliations

Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Saarland, D-66421 Homburg (Saar), Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12827635

Citation

Peters, Frank T., et al. "Screening for and Validated Quantification of Amphetamines and of Amphetamine- and Piperazine-derived Designer Drugs in Human Blood Plasma By Gas Chromatography/mass Spectrometry." Journal of Mass Spectrometry : JMS, vol. 38, no. 6, 2003, pp. 659-76.
Peters FT, Schaefer S, Staack RF, et al. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom. 2003;38(6):659-76.
Peters, F. T., Schaefer, S., Staack, R. F., Kraemer, T., & Maurer, H. H. (2003). Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. Journal of Mass Spectrometry : JMS, 38(6), 659-76.
Peters FT, et al. Screening for and Validated Quantification of Amphetamines and of Amphetamine- and Piperazine-derived Designer Drugs in Human Blood Plasma By Gas Chromatography/mass Spectrometry. J Mass Spectrom. 2003;38(6):659-76. PubMed PMID: 12827635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. AU - Peters,Frank T, AU - Schaefer,Simone, AU - Staack,Roland F, AU - Kraemer,Thomas, AU - Maurer,Hans H, PY - 2003/6/27/pubmed PY - 2003/12/12/medline PY - 2003/6/27/entrez SP - 659 EP - 76 JF - Journal of mass spectrometry : JMS JO - J Mass Spectrom VL - 38 IS - 6 N2 - The classical stimulants amphetamine, methamphetamine, ethylamphetamine and the amphetamine-derived designer drugs MDA, MDMA ('ecstasy'), MDEA, BDB and MBDB have been widely abused for a relatively long time. In recent years, a number of newer designer drugs have entered the illicit drug market. 4-Methylthioamphetamine (MTA), p-methoxyamphetamine (PMA) and p-methoxymethamphetamine (PMMA) are also derived from amphetamine. Other designer drugs are derived from piperazine, such as benzylpiperazine (BZP), methylenedioxybenzylpiperazine (MDBP), trifluoromethylphenylpiperazine (TFMPP), m-chlorophenylpiperazine (mCPP) and p-methoxyphenylpiperazine (MeOPP). A number of severe or even fatal intoxications involving these newer substances, especially PMA, have been reported. This paper describes a method for screening for and simultaneous quantification of the above-mentioned compounds and the metabolites p-hydroxyamphetamine and p-hydroxymethamphetamine (pholedrine) in human blood plasma. The analytes were analyzed by gas chromatography/mass spectrometry in the selected-ion monitoring mode after mixed-mode solid-phase extraction (HCX) and derivatization with heptafluorobutyric anhydride. The method was fully validated according to international guidelines. It was linear from 5 to 1000 micro g l(-1) for all analytes. Data for accuracy and precision were within required limits with the exception of those for MDBP. The limit of quantification was 5 micro g l(-1) for all analytes. The applicability of the assay was proven by analysis of authentic plasma samples and of a certified reference sample. This procedure should also be suitable for confirmation of immunoassay results positive for amphetamines and/or designer drugs of the ecstasy type. SN - 1076-5174 UR - https://www.unboundmedicine.com/medline/citation/12827635/Screening_for_and_validated_quantification_of_amphetamines_and_of_amphetamine__and_piperazine_derived_designer_drugs_in_human_blood_plasma_by_gas_chromatography/mass_spectrometry_ L2 - https://doi.org/10.1002/jms.483 DB - PRIME DP - Unbound Medicine ER -